RT Journal Article
SR Electronic
T1 A decade of dengue disease burden in Africa (2013–2023): a systematic review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.22.24315827
DO 10.1101/2024.10.22.24315827
A1 Mwanyika, Gaspary O.
A1 Moir, Monika
A1 Musa, Abdualmoniem O.
A1 Poongavanan, Jenicca
A1 Dor, Graeme
A1 Wilkinson, Eduan
A1 Baxter, Cheryl
A1 de Oliveira, Tulio
A1 Tegally, Houriiyah
YR 2024
UL http://medrxiv.org/content/early/2024/10/27/2024.10.22.24315827.abstract
AB Background Dengue is a major mosquito-borne disease worldwide. The epidemiological trends of the disease in Africa over the past decade remain unclear. This review aims to provide insight into the epidemiological trends of dengue in Africa from 2013-2023. Methods We systematically searched PubMed/MEDLINE and Scopus for studies published between January 2013 and December 2023. Additionally, we collected official records from the World Health Organization for Africa and African Centre for Disease Control. We included studies that reported dengue cases in humans in Africa and excluded publications prior to 2013, review articles and non-human studies. For specific countries, the suspected cases per 100,000 population and fatality rates were estimated and the trend predicted using a negative binomial model. The statistical analyses and visualisations were performed using R programming. Results Of the 453 reports screened, 87 from 25 African countries were selected for systematic review. Between 2013 and 2023, approximately 200,000 suspected dengue cases, 90,000 confirmed cases and 900 deaths were reported in Africa. Over 80% of confirmed cases originated from West Africa, with Burkina Faso reporting over 500 cases per 100,000 population. DENV1 and DENV2 predominating at different times with transmission closely linked to rainy seasons. Conclusions The rising dengue cases across Africa, highlight the need to strengthen surveillance and implement effective regional-specific interventions against future dengue outbreaks. Further research is necessary to improve our understanding on dengue transmission dynamics and suitability of regions in Africa.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch activities at KRISP and CERI are supported in part by grants from the Rockefeller Foundation (HTH 017), the Abbott Pandemic Defense Coalition (APDC), the National Institute of Health USA (U01 AI151698) for the United World Antivirus Research Network (UWARN), the SAMRC South African mRNA Vaccine Consortium (SAMVAC), the Global Health EDCTP3 Joint Undertaking and its members, as well as the Bill and Melinda Gates Foundation (101103171), the Health Emergency Preparedness and Response Umbrella Program (HEPR Program) managed by the World Bank Group (TF0B8412), the UK Medical Research Foundation (MRF-RG-ICCH-2022-100069), and the Wellcome Trust for the Global Health project (228186/Z/23/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We searched PubMed/MEDLINE and Scopus databases for relevant English articles using an advanced search strategy (Appendix S1). Additional epidemiological reports were obtained from the World Health Organization for Africa (WHO AFRO) and the African Centre for Disease Control (AFRICA CDC) between January 2013 and December 2023. We included articles that reported dengue cases in human studies in Africa and official records from the WHO AFRO and AFRICA CDC surveillance reportsI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll the relevant data are contained within the manuscript. Any additional data is made available through Mendeley data repository accessible at https://data.mendeley.com/my-data/https://data.mendeley.com/my-data/